MCF Advisors’s AstraZeneca AZN Stock Holding History

MCF Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.8K	Buy	75 +34	+83%	+$6.56K	﹤0.01%	884
2025 Q4	$7.54K	Buy	41 +38	+1,267%	+$6.67K	﹤0.01%	885
2025 Q3	$384	Buy	+3	New	+$454	﹤0.01%	927
2025 Q1	–	Sell	-7	Closed	-$852	–	922
2024 Q4	$852	Buy	+7	New	+$980	﹤0.01%	930
2023 Q3	–	Sell	-150	Closed	-$21.5K	–	924
2023 Q2	$21.5K	Hold	150	–	–	﹤0.01%	469
2023 Q1	$20.8K	Hold	150	–	–	﹤0.01%	470
2022 Q4	$20.3K	Hold	150	–	–	﹤0.01%	445
2022 Q3	$16K	Hold	150	–	–	﹤0.01%	489
2022 Q2	$20K	Buy	+150	New	+$19.7K	﹤0.01%	440

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

MCF Advisors's AZN Position: Q1 2026 in Review

MCF Advisors increased its AstraZeneca (AZN) stake by 83% in Q1 2026, buying an estimated $6.56K and bringing the position to 75 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

MCF Advisors first reported a position in AZN in Q2 2022 and has held it in 9 quarters since. The position peaked at $21.5K in Q2 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

MCF Advisors held 75 shares of AstraZeneca worth $14.8K as of Q1 2026.
MCF Advisors bought 34 AstraZeneca shares in Q1 2026, an estimated $6.56K.
AstraZeneca made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #884 holding.
MCF Advisors first reported a position in AstraZeneca in Q2 2022 and has held it in 9 quarters since.
MCF Advisors's AstraZeneca position peaked at $21.5K in Q2 2023.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.